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Abstract
Background: Surgical intervention is uncommon in chronic pancreatitis. Literature largely describes
single institution or international experiences. This study describes US-based chronic pancreatitis
surgical management.
Methods: Retrospective analysis of chronic pancreatitis patients in the Healthcare Cost and Utilization
Project Florida State Inpatient Database 2007–2011. Patients with malignancy or congenital abnormali-
ties were excluded. Univariate analysis using the chi-square test. The number of readmissions, inpa-
tient length of stay and cost using Wilcoxon’s signed-rank test. Multivariate analysis of surgery by
logistic regression.
Results: Twenty-one thousand four hundred and forty-five patients with chronic pancreatitis. 10.8%
(2 307) underwent surgery including 1652 cholecystectomies, 564 drainage procedures and 498 pan-
createctomies. Procedures decreased from 12.1% to 8.3% over time (P < 0.001), but intervention
within 3 months increased (7.2% to 8.4%; P = 0.017). 15.3% (3 278) had pancreatic cysts/pseudocysts
and 43.4% (9 312) had diabetes. The median numbers of admissions were 2 [interquartile range (IQR)
1,5] and 3 (IQR 2,7) among non-surgical and surgical patients, respectively (P < 0.001). Predictors of
surgery were fewer co-morbidities, private insurance, and either diabetes mellitus or pancreatic cyst/
pseudocyst.
Conclusion: Chronic pancreatitis leads to numerous inpatient readmissions, but surgical intervention
only occurs in a minority of cases. Complicated patients are more likely to undergo surgery. The com-
plexities of chronic pancreatitis management warrant early multidisciplinary evaluation and ongoing
consideration of surgical and non-surgical options.
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Background
Chronic pancreatitis is a serious and potentially debilitating
condition. Patients may develop complications including
chronic pain, weight loss, pancreatic endocrine or exocrine
insufficiency, malignancy, intestinal obstruction, haemorrhage
and acute fluid collections.1–4 The symptoms of chronic
pancreatitis, and often its aetiology, can be managed medically,
endoscopically and surgically.5–8.
Previous work has demonstrated that surgical management
of chronic pancreatitis, including extensive procedures such as
a pancreatectomy, can be performed with an acceptable risk
profile. Further, surgery offers more complete pain relief than
endoscopic interventions with no negative effect on long-term
mortality.2,9 US-based practice patterns outside of large,
academic institutions remain poorly characterized and the
This study was presented at the Annual Meeting of the AHPBA, 11–15
March 2015, Miami, Florida.
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ongoing impact on inpatient care utilization in chronic pancre-
atitis patients who do or do not receive surgery is unknown.
This study examined the utilization of surgery in the
inpatient management of chronic pancreatitis patients in a
US-based population cared for in a broad range of inpatient
centres. The timing and nature of surgical interventions, as
well as the associated inpatient outcomes, were analysed.
Patients and methods
Design
A retrospective review of the Healthcare Cost and Utilization
Project (HCUP) Florida State Inpatient Database (SID) was
performed. The SID is an administrative all-payer inpatient
discharge database assembled by the Agency for Healthcare
Research and Quality (AHRQ) HCUP.10 Patients can be fol-
lowed across time and institutions through the use of a unique
visit link variable. The database includes patient demographics,
hospital characteristics, and admission diagnosis codes, proce-
dure codes and charges.
Using ICD-9 diagnosis codes, all discharge records for
patients greater than or equal to 18 years of age during 2007 to
2011 with the diagnosis of chronic pancreatitis (ICD-9 577.1)
were identified. All subsequent inpatient admissions were
linked and analysed. Patients with evidence of anatomic anom-
alies of the pancreas (751.7) or neoplasms of the pancreas,
extrahepatic bile ducts or ampulla (156.1, 156.2, 156.8, 157,
211.6, 235.5, 230.9, 239.0) were excluded from analysis.
Patient characteristics
Patient demographic information collected from the initial
admission with coding of chronic pancreatitis included gender,
age, median ZIP code income, insurance type and race. The
patient comorbidity burden was calculated as an Elixhauser
score, generated using the HCUP Comorbidity Software, Ver-
sion 3.7.11 All inpatient admissions were queried to identify
chronic pancreatitis-related diagnoses for subset analysis: pan-
creatic cyst or pseudocyst (577.2), pancreatic steatorrhea
(579.4) and diabetes mellitus (249, 250).
Procedures
Chronic pancreatitis-related surgeries during the index or any
subsequent admissions were identified by ICD-9 procedure
code. Surgical procedures were divided into pancreatectomies
(52.22, 52.51, 52.52, 52.53, 52.59, 52.6, 52.7), drainage proce-
dures (52.3, 52.4, 52.96, 52.01, 52.09), sphincter-related proce-
dures (51.82, 51.83, 81.89) and cholecystectomies (51.21, 51.22,
51.23, 51.25) (Appendix A1). Surgeries performed among all
admissions as well as within 1 year of first admission and
within 3 months of first admission for patients with at least
1 year of follow-up time were identified. All inpatient endo-
scopic interventions were identified by ICD-9 procedure codes
(51.1, 51.64, 51.84, 51.85, 51.86, 51.87, 51.88, 52.13, 52.21,
52.93, 52.94, 52.97, 52.98).
Patient outcomes
The primary outcome was the number of inpatient admissions
occurring after the diagnosis of chronic pancreatitis, including
the first admission. Readmissions were identified using the
HCUP Supplemental Variables for revisit analyses. These pro-
vide unique visit links to allow patients to be tracked across all
inpatient admissions, including those that occur at other insti-
tutions in the state.10.
Other patient outcomes recorded were total inpatient length
of stay (LOS) across all admissions after a chronic pancreatitis
diagnosis, the number of inpatient admissions prior to any
surgical intervention, inpatient death and the total cost of all
inpatient care after chronic pancreatitis diagnosis. Further,
post-operative complications were identified for any admission
with a surgical procedure. Complications were identified using
secondary diagnosis codes and included infectious, respiratory,
cardiac, wound, thromboembolic and gastrointestinal compli-
cations.
Cost
The charge the hospital billed for each admission was
abstracted from the SID. To convert charge information to
approximate costs, the supplemental SID HCUP Cost-
to-Charge Ratio files were used.10 The costs for all inpatient
hospitalizations after chronic pancreatitis diagnosis were
aggregated for each patient.
Statistical analysis
Race and payer categories with a small number of patients
were collapsed into larger categories. Continuous variables,
age, median ZIP income and Elixhauser score, were categorized
to enhance clinical interpretability. Patient characteristics for
those patients with and without chronic pancreatitis-related
surgery were compared using chi-square tests. The presence of
chronic pancreatitis-related diagnoses and the use of endo-
scopic interventions in the surgical and non-surgical groups
were compared using chi-square tests.
Univariate regression modelling of the likelihood of under-
going chronic pancreatitis-related surgery was performed. A
multivariate regression model predicting chronic pancreatitis-
related surgery was created using all available patient predic-
tors, including chronic pancreatitis-related diagnoses.
Median values and interquartile ranges (IQRs) were calcu-
lated for the total number of inpatient admissions, days to the
surgical procedure, inpatient costs, inpatient LOS and the
number of endoscopic interventions. Outcomes were compared
by surgery status using Wilcoxon’s signed-rank test. Surgery
and endoscopic intervention rates during each time period
were analysed for trends over the course of the study using the
Cochran-Armitage trend test.
Owing to the broader range of indications for a cholecystec-
tomy, compared with a pancreatectomy, sphincter-related pro-
cedures and drainage procedures, a sensitivity analysis was
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performed. The likelihood of undergoing a non-cholecystec-
tomy surgical procedure was assessed using multivariate logis-
tic regression modelling and patient outcomes were analysed as
described above.
Statistical analyses were performed using SAS statistical
analysis software, version 9.3 (SAS Institute Inc., Cary, NC,
USA). A P-value of less 0.05 was considered statistically signifi-
cant for all analyses.
Results
Patient demographics
From 2007 to 2011, 21 445 patients experienced at least one
inpatient admission owing to chronic pancreatitis. The overall
population was largely white (15 2549, 71.1%), male (11 782,
54.9%), non-elderly (15 152, 70.7%), of lower ZIP-median
income quartiles (14 433, 67.3%), and had Elixhauser co-mor-
bidity scores of three or greater (13 089, 61.0%). In total, 2307
(10.8%) patients underwent a chronic pancreatitis-related sur-
gical procedure. Patients undergoing surgery had lower Elixha-
user co-morbidity scores (P < 0.001), a higher ZIP median
income quartile (P = 0.004) and higher rates of private insur-
ance (P < 0.001). Patient characteristics of patients with and
without surgery are included in Table 1.
Among patients without surgery, pancreatic endocrine insuf-
ficiency rate was 43.3% (8295 patients), and the rate of cysts
or pseudocysts was 12.5% (2 382 patients). 1071 (5.6%)
patients had both conditions. Among patients with chronic
pancreatitis-related surgery, pancreatic endocrine insufficiency
rate was 44.1% (1 017 patients), and the rate of cysts or pseud-
ocysts was 38.8% (896 patients). Four hundred and twenty-
three (18.3%) patients had both conditions. Pancreatic exo-
crine insufficiency was an uncommon inpatient diagnosis (<11
patients).
Procedures
Two thousand three hundred and seven (10.8%) patients
underwent a chronic pancreatitis-related surgical procedure.
One thousand six hundred and fifty-two patients (71.6% of
the surgery group, 7.7% of overall population) underwent
cholecystectomies. Five hundred and sixty-four patients (24.4%
of the surgery group, 2.6% of overall population) underwent
drainage procedures. Four hundred and ninety-eight patients
(21.6% of the surgery group, 2.3% of overall population)
underwent pancreatectomies. Thirty-six patients (1.6% of the
surgery group, 0.2% of overall population) underwent sphinc-
ter procedures. 82.8% of all surgical patients (1911 patients)
underwent only one procedure type, whereas 329 patients
(14.3%) and 56 (2.4%) underwent two procedure types or
three to four procedure types, respectively.
Upon multivariate logistic regression, significant predictors
of not receiving surgery were an increasing Elixhauser co-mor-
bidity score and non-private insurance. Patients with diabetes
mellitus or pancreatic cyst or pseudocyst were more likely to
receive a surgical intervention. Unadjusted and adjusted odds
ratios are presented in Table 2.
The overall rate of surgery decreased from first admission
year of 2007 to 2011 (P < 0.001), not adjusting for the length
of follow-up. When restricting to surgeries performed within
1 year of first admission among those with at least 1 year fol-
low-up there is no significant trend (P = 0.084), but there is
an increase in procedures performed within 3 months of the
first inpatient admission (P = 0.017). Rates of surgery by year
of first admission are displayed in Fig. 1a. When examining a
pancreatectomy only, the overall rates decreased during the
study period (P = 0.033) (Fig. 1b).
Two thousand two hundred and fifty-one patients (10.5%)
underwent endoscopic interventions. Patients managed with
surgery were more likely to undergo at least one endoscopic
intervention [29.8% (688 patients) versus 8.2% (1563 patients);
P < 0.001]. Among those who underwent endoscopic interven-
tions, the median number of endoscopic procedures was 1
[IQR 1,1] and ranged from 1 to more than 6 procedures. Over
Table 1 Chronic pancreatitis patient characteristics by surgical
procedure status
No surgery Surgery P-value
n (%) n (%)
Age >65 years 5645 (29.5) 648 (28.9) 0.161
Female 8660 (45.3) 1003 (43.48) 0.106
White 13 584 (71.0) 1665 (72.2) 0.233
Elixhauser
0 966 (5.1) 225 (9.8) <0.001
1 2528 (13.2) 373 (16.2)
2 3772 (19.7) 492 (21.3)
3+ 11 872 (62.0) 1 217 (52.8)
Income quartile
Lowest 6661 (34.8) 717 (31.1) 0.004
Lower Middle 6259 (32.7) 796 (34.5)
Upper Middle 4478 (23.4) 583 (25.7)
Highest 1740 (9.1) 211 (9.2)
Insurance
Medicare 8335 (43.6) 873 (37.8) <0.001
Medicaid 2547 (13.3) 303 (13.1)
Private 4033 (21.1) 697 (30.2)
Missing/Other 4223 (22.1) 434 (18.8)
Year of first admission
2007 4497 (23.5) 621 (26.9) <0.001
2008 3747 (19.6) 462 (20.0)
2009 3702 (19.3) 475 (20.6)
2010 3620 (18.9) 424 (18.4)
2011 3572 (18.7) 325 (14.1)
Bold values are statistically significant.
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the course of the study, the rates of endoscopic intervention
decreased from 12.8% (657 patients) in 2007 to 7.8% (305
patients) in 2011 (P < 0.001).
Outcomes
The receipt of surgery was associated with a greater total num-
ber of admissions, a higher total inpatient LOS and a larger
total inpatient cost of care (all P < 0.001; Table 3). Prior to
surgical intervention, those patients undergoing a pancreatec-
tomy had a median number of inpatient admissions of 1 [IQR
0,2] whereas the median for those undergoing drainage proce-
dures, cholecystectomies and sphincter-related procedures were
1 [0,3], 0 [0,2] and 2 [0,4], respectively.
Overall inpatient mortality rates were lower among those
undergoing chronic pancreatitis-related surgery [6.6% (152
patients) versus 8.7% (1 670 patients), P = 0.0001]. Inpatient
mortality rates and the proportion of deaths occurring during
first chronic pancreatitis-related admission are displayed in
Fig. 2. Among those who underwent surgical intervention, the
complication rate was 29.8% (688 patients). Complication rates
were 46.4% (231 patients) for a pancreatectomy, 34.9% (197
patients) for drainage procedures, 30.6% (11 patients) for
sphincter procedures and 26.7% (441 patients) for a cholecys-
tectomy. The complication rate for those undergoing endo-
scopic interventions was 10.0% (224 patients). Over time, the
rates of post-operative complications remained stable
(P = 0.651).
Sensitivity analysis
With the exclusion of cholecystectomy, the overall rate of sur-
gical procedures decreased to 4.6% (975 patients). Among this
population, 93.0% (907 patients) had at least one chronic pan-
creatitis-related diagnosis, including 709 (72.7%) with a pan-
creatic cyst or pseudocyst. The majority (74.6%) of cases were
performed emergently and the overall rate of surgeries
Table 2 Adjusted and unadjusted logistic regression models predicting odds of undergoing surgical procedures for chronic pancreatitis
Unadjusted Adjusted
Odds Ratio 95% Confidence
Interval
Odds Ratio 95% Confidence
Interval
Female (versus male) 0.931 0.853 1.015 1.019 0.930 1.116
Elixhauser Score (versus 0)
1 0.633 0.528 0.759 0.617 0.511 0.745
2 0.560 0.471 0.666 0.535 0.446 0.642
≥3 0.440 0.376 0.515 0.416 0.351 0.493
Low Income (versus high) 0.917 0.837 1.005 0.987 0.897 1.086
Age (in years) 0.993 0.990 0.996 0.998 0.994 1.001
Insurance (versus Private)
Medicare 0.606 0.545 0.674 0.799 0.703 0.908
Medicaid 0.688 0.596 0.795 0.786 0.675 0.915
Missing/Other 0.595 0.524 0.675 0.601 0.526 0.687
White Race (versus Non-white) 0.943 0.857 1.038 1.013 0.914 1.122
Pancreatic Cyst or Pseudocyst 4.467 4.066 4.908 4.470 4.060 4.921
Diabetes Mellitus 1.031 0.945 1.124 1.144 1.039 1.259
Bold values are statistically significant.
(a)
(b)
Figure 1 Rates of (a) any surgical procedure and (b) pancreatectomy
for chronic pancreatitis at any time, within 1 year of first inpatient
admission and within 3 months of first inpatient admission
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decreased over the study period from 4.9% (253 patients) in
2007 to 3.8% (146 patients) in 2011 (P = 0.005). Upon multi-
variate modelling, significant predictors of undergoing a sur-
gery other than a cholecystectomy were the presence of a
pancreatic cyst or pseudocyst [odds ratio (OR) 18.229; 95%
confidence interval (CI) 15.705, 21.159] and the presence of
diabetes mellitus (OR 1.314; 95% CI 1.135, 1.523). Higher
Elixhauser co-morbidity scores and increasing age were associ-
ated with a decreased likelihood of undergoing surgery. The
median total LOS was 32 days (IQR 16, 59) and the median
total cost of care was $59 947 (IQR $33 980, $105 543).
Seventy-two patients (7.4%) died during the study period.
Discussion
This study determined that in a large, diverse US state the
minority of chronic pancreatitis patients undergo surgery.
Those who receive surgery are more likely also to be diagnosed
with diabetes mellitus and have an ICD-9 diagnosis code of
either pancreatic cysts or pseudocysts. When excluding chole-
cystectomy, pancreatic cyst or pseudocyst is an extremely
strong predictor of surgical management. Patients with a large
number of co-morbid conditions and non-private insurance
are less likely to undergo surgery. Those patients who undergo
surgery have higher admission rates, longer total inpatient
LOSs and higher total inpatient costs of care, but similar
mortality rates compared with those patients who do not
undergo surgery. While the overall use of surgery has decreased
across the study period, the rate of early surgery, performed
within 3 months of first inpatient chronic pancreatitis admis-
sion, has increased. The use of endoscopic interventions has
decreased over time but is more common in patients who
receive surgery.
Surgical management for chronic pancreatitis can produce
sustained relief of pain and restore quality of life. The poor
health of many chronic pancreatitis patients suggests operative
intervention may only be appropriate in a highly select popu-
lation.2,12–15 However, in-hospital mortality rates are signifi-
cantly lower for patients undergoing resection for pancreatitis
compared with malignant neoplasm, suggesting pancreatec-
tomy for chronic pancreatitis is an acceptably safe procedure.16
Similarly, post-operative morbidity rates are acceptable given
the extensive nature of these procedures.17 Surgical manage-
ment offers more definitive relief of pain and resolution of
biliary obstruction than endoscopic management.7,9,18,19 Fur-
ther, surgical management of pancreatic pseudocysts may
reduce inpatient morbidity compared with percutaneous man-
agement and may reduce the risk of pancreatic cancer develop-
ment.20,21
The timing of the operative management of chronic pancre-
atitis remains controversial.22 Multiple studies suggest that sur-
gical intervention before the start of opioid dependence may
be beneficial.23,24 While the ESCAPE trial aims to address
definitively the choice between a step-up approach versus early
surgery, recent retrospective analyses suggest earlier surgical
intervention improves patient symptoms.22,25 In our recent sys-
tematic review and meta-analysis, patients who received early
surgery had an increased likelihood of complete post-operative
pain relief and a reduced risk of pancreatic insufficiency when
compared with those undergoing late surgery.26
The vast majority of studies addressing the use of surgery in
chronic pancreatitis compare patients treated at high-volume,
academic centres. In this study, it is demonstrated that at a
population level surgery is uncommonly deployed in the man-
agement of chronic pancreatitis. Those who undergo surgery
place a greater burden on the inpatient care system, although
it is not clear whether this reflects a higher severity of disease
in this population or adverse effects of large operative inter-
ventions. Surgical intervention is not evenly deployed across all
Figure 2 Inpatient mortality among all inpatient admissions and
during the first inpatient admission for chornic pancreatitis patients
who did and did not undergo surgery
Table 3 Admission patterns and outcomes for chronic pancreatitis patients undergoing and not undergoing surgery
No Surgery Surgery P-value
Median [IQR] Median [IQR]
Inpatient Admissions 2 [1, 5] 3 [2, 7] <0.001
Total Inpatient LOS (days) 13 [5, 30] 24 [10, 52] <0.001
Total Inpatient Cost (US$) $20 694 [$8849, $49 653] $45 072 [$20 700, $90 965] <0.001
IQR, interquartile range; LOS, length of stay.
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patient populations as patients with private insurance are more
likely to receive surgical management.
Our analysis is a retrospective review, so the use of surgery
is not random. The sickest patients may not survive to surgery,
whereas patients with a more severe disease requiring more fre-
quent, lengthy inpatient hospitalizations may be more likely to
receive surgery. Further, the utilization of an administrative
database presents several limitations. Clinical information,
including pain scores and disease severity, is lacking, and data
are subject to miscoding. The single ICD-9 diagnosis of code
for both pancreatic cysts and pseudocysts prevents identifica-
tion of resections performed for potential neoplasms compared
with those performed for other CP-related indications. Addi-
tionally, some clinical diagnoses, such as steatorrhoea, may be
unreported in the inpatient setting. Physician identity and spe-
cialty cannot be established using the SID, so we are unable to
assess the role of multidisciplinary care teams or how physician
specialty influences time to receipt of surgery. Finally, the SID
only captures inpatient care, so outpatient procedures, particu-
larly endoscopy, are not reflected in the present results.
Despite these limitations, this study represents the largest
population-based analysis of surgical practices in the setting of
chronic pancreatitis. It provides longitudinal data about a large
group of subjects who receive care at non-academic medical
centres and possibly multiple facilities. Additionally, this popu-
lation-level data will provide a broader context for the pending
ESCAPE trial findings, given the study enrollment limitations
of randomized controlled trials.22
Chronic pancreatitis can lead to persistent pain and pancre-
atic insufficiency among other devastating outcomes. Surgical
management is an infrequently utilized, viable management
strategy that can be associated with improved long-term out-
comes. While surgically managed patients have an increased
burden on the inpatient care system, this may reflect the cur-
rent selection of patients with severe disease. Literature sug-
gests that earlier surgical intervention may reduce the need for
prolonged opioid pain management and our findings suggest a
shift towards earlier surgical intervention over time. Additional
prospective studies of the surgical management of chronic pan-
creatitis are needed to determine optimal timing and patient
selection to improve patient outcomes and reduce utilization
of inpatient healthcare services.
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Appendix A1
Category ICD-9
Procedure
Code
Procedure
Cholecystectomies 51.21 Other partial cholecystectomy
51.22 Cholecystectomy
51.23 Laparoscopic cholecystectomy
51.25 Laparoscopic partial
cholecystectomy
Drainage
Procedures
43.0 Gastrostomy
43.19 Other gastrostomy
46.32 Percutaneous jejunostomy
46.39 Other enterostomy
52.01 Drainage of pancreatic cyst
by catheter
52.09 Other pancreatotomy
52.3 Marsupialization of pancreatic
cyst
52.4 Internal drainage of pancreatic
cyst
52.96 Anastomosis of pancreas
Appendix Continued
Category ICD-9
Procedure
Code
Procedure
Endoscopic
Procedures
51.1 Endoscopic retrograde
cholangiopancreatography
(ERCP)
51.64 Endoscopic excision or
destruction of lesion of biliary
ducts or sphincter of Oddi
51.84 Endoscopic dilation of ampulla
and biliary duct
51.85 Endoscopic sphincterotomy and
papillotomy
51.86 Endoscopic insertion of
nasobiliary drainage tube
51.87 Endoscopic insertion of stent
(tube) into bile duct
51.88 Endoscopic removal of stone(s)
from biliary tract
52.13 Endoscopic retrograde
pancreatography (ERP)
52.21 Endoscopic excision or
destruction of lesion or tissue
of pancreatic duct
52.93 Endoscopic insertion of stent
(tube) into pancreatic duct
52.94 Endoscopic removal of stone(s)
from pancreatic duct
52.97 Endoscopic insertion of
nasopancreatic drainage tube
52.98 Endoscopic dilation of
pancreatic duct
Pancreatectomies 52.22 Other excision or destruction of
lesion or tissue of pancreas or
pancreatic duct
52.51 Proximal pancreatectomy
52.52 Distal pancreatectomy
52.53 Radical subtotal
pancreatectomy
52.59 Other partial pancreatectomy
52.6 Total pancreatectomy
52.7 Radical
pancreaticoduodenectomy
Sphincter-related
procedures
51.82 Pancreatic sphincterotomy
51.83 Pancreatic sphincteroplasty
81.89 Other operations on sphincter of
Oddi
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